Aveo ISIN: US0535883070 Forum: Aktien User: Gambler10101

👀

https://www.globenewswire.com/news-release/2022/03/14/2402410/0/en/AVEO-Oncology-Reports-Full-Year-and-Fourth-Quarter-2021-Financial-Results.html

https://finance.yahoo.com/news/actinium-pharmaceuticals-inc-aveo-oncology-130000958.html

https://www.globenewswire.com/news-release/2022/02/14/2384775/0/en/AVEO-Oncology-to-Present-Positive-New-Long-Term-PFS-Data-from-Phase-3-TIVO-3-Study-of-FOTIVDA-tivozanib-in-Third-and-Fourth-Line-Renal-Cell-Carcinoma.html

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-reports-q3-loss-tops-revenue-estimates

https://seekingalpha.com/article/4463396-aveo-oncology-sticking-plan

https://www.businesswire.com/news/home/20210920005338/en/AVEO-Oncology-Announces-Ficlatuzumab-Granted-Fast-Track-Designation-by-the-U.S.-FDA-for-the-Treatment-of-Relapsed-or-Recurrent-Head-and-Neck-Squamous-Cell-Carcinoma.

AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20210805005952/en/AVEO-Oncology-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update – Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021 – – COVID-19 Related Manufacturing Supply Shortages to Push Potential Registrational Study Start for Ficlatuzumab to 2023 – ...

Okay

http://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-us-fda-approval-fotivdar-tivozanib

Das ist von Mörz! 😂

Danke

Zulassung von"Tivozanip"

"Aveo Onkologie"